{"nctId":"NCT05836012","briefTitle":"Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines","startDateStruct":{"date":"2023-06-10","type":"ACTUAL"},"conditions":["Gastroenteritis"],"count":329,"armGroups":[{"label":"Experimental","type":"EXPERIMENTAL","interventionNames":["Biological: HIL-214"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"HIL-214","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The subject is aged 2 months (+14 days).\n* Male or female.\n* Infants who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.\n* The subject's LAR signs and dates a written, informed consent form (ICF) and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.\n* Infants whose LARs can and are willing to comply with trial procedures and are available for the duration of follow-up.\n\nExclusion Criteria:\n\n* Clinically significant abnormality in growth by height, weight, or head circumference (according to local guidelines).\n* Gastrointestinal abnormalities or any chronic gastrointestinal disease, including any uncorrected congenital malformation of the gastrointestinal tract according to medical history and/or physical examination.\n* Known hypersensitivity or allergy to any of the investigational vaccine components (including excipients).\n* Severe reaction to routine childhood vaccine(s) administered at Visit 1.\n* Any clinically significant active infection (as assessed by the investigator) or temperature\n\n  ≥38.0°C (\\>100.4°F), within 3 days of intended trial vaccination.\n* Any serious chronic or progressive disease according to the judgment of the investigator (e.g., cardiac, renal or hepatic disease).\n* Individuals with history of, e.g., convulsions/febrile convulsions, or any illness, that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the subjects due to participation in the trial.\n* Known or suspected impairment/alteration of immune function.\n* Subjects with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.\n* Subjects who received or are scheduled to receive any licensed or authorized vaccines not planned in this trial within 14 days (for inactivated vaccines) or within 28 days (for live vaccines) before or after any dose of trial vaccine. Note: Flu and/or COVID vaccine can be administered per local guidelines at any time during the trial.\n* Subjects participating in any clinical trial with another investigational product 30 days prior to first trial visit or due to participate in another clinical trial at any time during the conduct of this trial.\n* Subjects known to be positive for or in evaluation for possible human immunodeficiency virus infection.\n* Subject's LAR or subject's first-degree relatives involved in the trial conduct.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","maximumAge":"2 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Immune Response to the Licensed Pediatric DTaP-Hib-IPV-HepB Vaccine Co-administered With a 2-dose Regimen of HIL-214 at 4 and 6 Months of Age, Compared to That of the Routine Pediatric Vaccines Co-administered With Placebo.","description":"Evaluate the immune response to the licensed pediatric DTaP-Hib-IPV-HepB vaccine co-administered with a 2-dose regimen of HIL-214 at 4 and 6 months of age, compared to that of the routine pediatric vaccine co-administered with placebo. Due to differing local availability of licensed DTaP-Hib-IPV-HepB vaccine, data are presented by country (Panama and USA).\n\nOutcome measures:\n\n* Binary (yes/no) variable indicating anti-DT immunoglobulin G (IgG) concentration ≥0.1 IU/mL.\n* Binary variable indicating anti-TT IgG concentration ≥0.1 IU/mL.\n* Anti-pertussis \\[FHA\\], \\[PRN\\] and \\[PTX\\]) IgG concentrations.\n* Binary variable indicating anti-poliovirus neutralizing antibody titers ≥1:8,\n* Binary variable indicating anti-Haemophilus influenzae type b\n* Binary variable indicating anti-hepatitis b surface antigen\n\nGeometric mean (geometric mean standard deviation) anti-FHA, anti-PRN, and anti-PTX are presented as a separate outcome.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"99.2","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Immune Response to the Licensed Pediatric DTaP-Hib-IPV-HepB Vaccine Co-administered With a 2-dose Regimen of HIL-214 at 4 and 6 Months of Age, Compared to That of the Routine Pediatric Vaccines Co-administered With Placebo.","description":"Evaluate the immune response to the licensed pediatric DTaP-Hib-IPV-HepB vaccine co-administered with a 2-dose regimen of HIL-214 at 4 and 6 months of age, compared to that of the routine pediatric vaccine co-administered with placebo. Due to differing local availability of licensed DTaP-Hib-IPV-HepB vaccine, data are presented by country (Panama and USA).\n\nOutcome measures:\n\nGeometric mean anti-FHA, anti-PRN, and anti-PTX concentrations","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.958","spread":"1.8338"},{"groupId":"OG001","value":"78.726","spread":"1.8566"},{"groupId":"OG002","value":"32.515","spread":"2.9346"},{"groupId":"OG003","value":"26.358","spread":"2.7499"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.605","spread":"2.1811"},{"groupId":"OG001","value":"84.617","spread":"2.2496"},{"groupId":"OG002","value":"61.222","spread":"2.6526"},{"groupId":"OG003","value":"43.417","spread":"2.7743"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.536","spread":"1.8552"},{"groupId":"OG001","value":"48.906","spread":"2.0150"},{"groupId":"OG002","value":"80.713","spread":"2.2249"},{"groupId":"OG003","value":"43.066","spread":"2.5144"}]}]}]},{"type":"PRIMARY","title":"Immune Response to the Licensed Pediatric Pneumococcal 13 Valent (PCV13) Vaccine Co-administered With a 2-dose Regimen of HIL-214 at 4 and 6 Months of Age, Compared to That of the Routine Pediatric Vaccines Co-administered With Placebo.","description":"The outcome was assessed using measurements of immune response to the concomitant anti-pneumococcal capsular polysaccharide IgG \\[serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 18C, and 23F\\]) at 28 days post-dose. Geometric mean concentrations are presented.","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.255","spread":"1.9827"},{"groupId":"OG001","value":"5.802","spread":"2.2008"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.777","spread":"2.3728"},{"groupId":"OG001","value":"0.747","spread":"2.2117"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.958","spread":"1.8468"},{"groupId":"OG001","value":"2.773","spread":"2.0253"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.378","spread":"1.9223"},{"groupId":"OG001","value":"2.429","spread":"1.9277"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.660","spread":"2.0384"},{"groupId":"OG001","value":"7.414","spread":"2.2194"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.419","spread":"2.3854"},{"groupId":"OG001","value":"5.459","spread":"2.7604"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.091","spread":"1.6726"},{"groupId":"OG001","value":"5.063","spread":"1.7727"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.881","spread":"1.9259"},{"groupId":"OG001","value":"3.568","spread":"2.1651"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.819","spread":"2.3158"},{"groupId":"OG001","value":"12.017","spread":"2.3278"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.203","spread":"2.0635"},{"groupId":"OG001","value":"3.069","spread":"1.9742"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.822","spread":"2.0030"},{"groupId":"OG001","value":"5.487","spread":"2.1713"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.997","spread":"1.8435"},{"groupId":"OG001","value":"3.040","spread":"1.9344"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.885","spread":"2.5878"},{"groupId":"OG001","value":"2.543","spread":"2.7745"}]}]}]},{"type":"PRIMARY","title":"Immune Response to the Licensed Pediatric Rotavirus Vaccine (RV1) Vaccine Co-administered With a 2-dose Regimen of HIL-214 at 4 and 6 Months of Age, Compared to That of the Routine Pediatric Vaccines Co-administered With Placebo.","description":"This outcome was assessed using measurements of immune response to the concomitant RV1 vaccine (anti-RV1 IgA). Geometric mean concentrations at 28 days post-dose 2 are reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.772","spread":"4.0633"},{"groupId":"OG001","value":"87.694","spread":"4.2618"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of a 2-dose Regimen of HIL-214 Co-administered With Routine Pediatric Vaccines at 4 and 6 Months of Age.","description":"Anti-norovirus (GI.1 and GII.4c) HBGA-blocking antibodies were measured at prior to dose 1 (\\~4 months of age) and 28 days post-dose 2 (\\~6 months of age). Seroresponse was defined as a fold increase from baseline greater than or equal to 4. Seroresponse rates and 95% confidence intervals (CIs) are presented. Data are stratified by country (Panama and USA).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"97.5","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"51.3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"53.0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"16.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluate the Safety Profile of a 2-dose Regimen of HIL-214 Co-administered With Routine Pediatric Vaccines at 4 and 6 Months of Age, Compared to That of the Routine Pediatric Vaccines Co-administered With Placebo.","description":"Percentage of participants with solicited local (injection site) reactions within 7 days of any vaccine administration. Assessed reactions included pain, redness, induration, and swelling.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","spread":null},{"groupId":"OG001","value":"41.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluate the Safety Profile of a 2-dose Regimen of HIL-214 Co-administered With Routine Pediatric Vaccines at 4 and 6 Months of Age, Compared to That of the Routine Pediatric Vaccines Co-administered With Placebo.","description":"Percentage of participants with solicited systemic adverse events (AEs) within 7 days of any vaccine administration. Assessed AEs included drowsiness, irritability/fussiness, loss of appetite, fever, vomiting, and diarrhea.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":null},{"groupId":"OG001","value":"46.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluate the Safety Profile of a 2-dose Regimen of HIL-214 Co-administered With Routine Pediatric Vaccines at 4 and 6 Months of Age, Compared to That of the Routine Pediatric Vaccines Co-administered With Placebo.","description":"Percentage of participants with adverse events (AEs) leading to vaccine discontinuation or trial withdrawal.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluate the Safety Profile of a 2-dose Regimen of HIL-214 Co-administered With Routine Pediatric Vaccines at 4 and 6 Months of Age, Compared to That of the Routine Pediatric Vaccines Co-administered With Placebo","description":"Percentage of participants with medically attended adverse events (AEs) at any point during the trial.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.4","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":164},"commonTop":["Nasopharyngitis","Gastroenteritis","Bronchiolitis","Pyrexia"]}}}